Treatment-Resistant Depression in Adolescents: Recognition and Management

[1]  Abraham Weizman,et al.  Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. , 2007, Journal of child and adolescent psychopharmacology.

[2]  Golda S. Ginsburg,et al.  Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). , 2006, Journal of the American Academy of Child and Adolescent Psychiatry.

[3]  B. Birmaher,et al.  Acute Antidepressant Response and Plasma Levels of Bupropion and Metabolites in a Pediatric-Aged Sample: An Exploratory Study , 2006, Therapeutic drug monitoring.

[4]  R. Findling,et al.  Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study. , 2006, Journal of child and adolescent psychopharmacology.

[5]  F. Lotufo-Neto,et al.  Group cognitive-behavioral therapy versus sertraline for the treatment of children and adolescents with obsessive-compulsive disorder. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[6]  J. Powell,et al.  A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[7]  Barry R. Rittberg,et al.  A One-Year Comparison of Vagus Nerve Stimulation with Treatment as Usual for Treatment-Resistant Depression , 2005, Biological Psychiatry.

[8]  P. Berney.  Dose-response relationship of recent antidepressants in the short-term treatment of depression , 2005, Dialogues in clinical neuroscience.

[9]  J. Markowitz,et al.  Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. , 2005, Archives of general psychiatry.

[10]  B. Birmaher,et al.  Platelet serotonin reuptake inhibition and response to SSRIs in depressed adolescents. , 2005, The American journal of psychiatry.

[11]  Michael Shannon,et al.  The serotonin syndrome. , 2005, The New England journal of medicine.

[12]  B. Birmaher,et al.  Treatment guidelines for children and adolescents with bipolar disorder. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[13]  J. Seeley,et al.  Potential mediators of cognitive-behavioral therapy for adolescents with comorbid major depression and conduct disorder. , 2005, Journal of consulting and clinical psychology.

[14]  J. McCracken,et al.  Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[15]  D. Fergusson,et al.  Asthma and depressive and anxiety disorders among young persons in the community , 2004, Psychological Medicine.

[16]  M. Thase.  Therapeutic Alternatives for Difficult-to-Treat Depression: A Narrative Review of the State of the Evidence , 2004, CNS Spectrums.

[17]  Benedetto Vitiello,et al.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. , 2004, JAMA.

[18]  R. Rosenheck,et al.  Age effects on antidepressant-induced manic conversion. , 2004, Archives of pediatrics & adolescent medicine.

[19]  A. Albano,et al.  Cognitive-behavioral psychotherapy for anxiety and depressive disorders in children and adolescents: an evidence-based medicine review. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[20]  P. Höglund,et al.  Serum disposition of sertraline, N‐desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression , 2004, Human psychopharmacology.

[21]  J. Seeley,et al.  An efficacy/effectiveness study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[22]  Richard A. Brown,et al.  Psychiatric disorders, familial factors, and cigarette smoking: III. Associations with cessation by young adulthood among daily smokers. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[23]  R. Armitage,et al.  Rest-activity cycles in childhood and adolescent depression. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[24]  J. Seeley,et al.  Pilot evaluation of the Coping Course: a cognitive-behavioral intervention to enhance coping skills in incarcerated youth. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[25]  M. Weissman,et al.  A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. , 2004, Archives of general psychiatry.

[26]  R. Findling,et al.  A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. , 2004, The American journal of psychiatry.

[27]  C. Normann,et al.  Paroxetine in major depression: correlating plasma concentrations and clinical response. , 2004, Pharmacopsychiatry.

[28]  R. Lam,et al.  Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. , 2004, The Journal of clinical psychiatry.

[29]  B. Birmaher,et al.  Suicidality and its relationship to treatment outcome in depressed adolescents. , 2004, Suicide & life-threatening behavior.

[30]  Richard A. Brown,et al.  Psychiatric disorders, familial factors, and cigarette smoking: II. Associations with progression to daily smoking. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[31]  M. Thase.  Achieving remission and managing relapse in depression. , 2003, The Journal of clinical psychiatry.

[32]  D. Fergusson,et al.  Deviant Peer Affiliations and Depression: Confounding or Causation? , 2003, Journal of abnormal child psychology.

[33]  B. Rothbaum,et al.  Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Rosenberg,et al.  Neurochemical analyses in pediatric obsessive-compulsive disorder in patients treated with cognitive-behavioral therapy. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[35]  S. Plioplys.  Depression in children and adolescents with epilepsy , 2003, Epilepsy & Behavior.

[36]  K. Meador,et al.  Rates and risk factors for suicide, suicidal ideation, and suicide attempts in chronic epilepsy , 2003, Epilepsy & Behavior.

[37]  P. Fitzgerald,et al.  Transcranial magnetic stimulation in the treatment of depression: a double-blind, placebo-controlled trial. , 2003, Archives of general psychiatry.

[38]  P. Joyce,et al.  Age may affect response to antidepressants with serotonergic and noradrenergic actions. , 2003, Journal of affective disorders.

[39]  I. Katz,et al.  Effect of Increasing the Dose and Duration of Sertraline Trial in the Treatment of Depressed Nursing Home Residents , 2003, Journal of geriatric psychiatry and neurology.

[40]  K. Otani,et al.  Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients , 2003, Psychopharmacology.

[41]  J. Calabrese,et al.  A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. , 2003, Archives of general psychiatry.

[42]  F. L. Rocha,et al.  Lamotrigine augmentation in unipolar depression , 2003, International clinical psychopharmacology.

[43]  W. Slikker,et al.  Adolescent nicotine administration alters serotonin receptors and cell signaling mediated through adenylyl cyclase , 2002, Brain Research.

[44]  M. Trivedi,et al.  The DOSE study: a clinical trial to examine efficacy and dose response of exercise as treatment for depression. , 2002, Controlled clinical trials.

[45]  A. Ghanizadeh,et al.  Various Types of Exercise and Scores on the Beck Depression Inventory , 2002, Psychological reports.

[46]  J. Garber,et al.  Depressive spectrum disorders in high-risk adolescents: episode duration and predictors of time to recovery. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[47]  M. Thase.  What role do atypical antipsychotic drugs have in treatment-resistant depression? , 2002, The Journal of clinical psychiatry.

[48]  D. Kupfer,et al.  Screening for anxiety and depression in early adolescence. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[49]  P. Kendall,et al.  Examining Outcome Variability: Correlates of Treatment Response in a Child and Adolescent Anxiety Clinic , 2001, Journal of clinical child psychology.

[50]  D. Streiner,et al.  Antidepressants plus benzodiazepines for major depression , 2001 .

[51]  N. Ryan,et al.  Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[52]  S. Greenwald,et al.  Psychosocial and risk behavior correlates of youth suicide attempts and suicidal ideation. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[53]  P. Lewinsohn,et al.  Impact of comorbidity on a cognitive-behavioral group treatment for adolescent depression. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[54]  M. Weissman,et al.  The association between childhood depression and adulthood body mass index. , 2001, Pediatrics.

[55]  Debbie A Lawlor,et al.  The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials , 2001, BMJ : British Medical Journal.

[56]  P. Bentivoglio,et al.  Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. , 2001, Journal of the American Academy of Child and Adolescent Psychiatry.

[57]  M. Resnick,et al.  Adolescent suicide attempts: risks and protectors. , 2001, Pediatrics.

[58]  D. Kupfer,et al.  Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression , 2000, Neuropsychopharmacology.

[59]  M. Keshavan,et al.  Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.

[60]  B. Birmaher,et al.  Cognitive and family therapies for adolescent depression: treatment specificity, mediation, and moderation. , 2000, Journal of consulting and clinical psychology.

[61]  A. Gelenberg,et al.  Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. , 2000, JAMA.

[62]  J. Markowitz,et al.  A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. , 2000, The New England journal of medicine.

[63]  J. Rapoport,et al.  Practitioner Review: Treatment of Obsessive-Compulsive Disorder in Children and Adolescents , 2000 .

[64]  J. Kaprio,et al.  Familial association between allergic disorders and depression in adult Finnish twins. , 2000, American journal of medical genetics.

[65]  M Strober,et al.  The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[66]  J. Bridge,et al.  Outcome at 6 months for 50 adolescents with major depression treated in a health maintenance organization. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[67]  M. Bauer,et al.  Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. , 1999, Journal of clinical psychopharmacology.

[68]  G. Bernal,et al.  The efficacy of cognitive-behavioral and interpersonal treatments for depression in Puerto Rican adolescents. , 1999, Journal of consulting and clinical psychology.

[69]  J. Teasdale,et al.  Prevention of relapse in residual depression by cognitive therapy: a controlled trial. , 1999, Archives of general psychiatry.

[70]  R. Findling,et al.  Paroxetine pharmacokinetics in depressed children and adolescents. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[71]  P. Boyer,et al.  Venlafaxine and paroxetine in treatment-resistant depression , 1999, British Journal of Psychiatry.

[72]  J. Guelfi,et al.  [Is there a relationship between clinical efficacy and antidepressant dosage in major depression?]. , 1999, L'Encephale.

[73]  M. Weissman,et al.  Efficacy of interpersonal psychotherapy for depressed adolescents. , 1999, Archives of general psychiatry.

[74]  P. Lewinsohn,et al.  Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[75]  J. Calabrese,et al.  A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. , 1999, The Journal of clinical psychiatry.

[76]  J. Amsterdam,et al.  Treatment resistant depression: methodological overview and operational criteria , 1999, European Neuropsychopharmacology.

[77]  P. McGuffin,et al.  Validity of the shortened Mood and Feelings Questionnaire in a community sample of children and adolescents: a preliminary research note , 1998, Psychiatry Research.

[78]  B. Birmaher,et al.  Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. American Academy of Child and Adolescent Psychiatry. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[79]  P. Lewinsohn,et al.  Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. , 1998, Clinical psychology review.

[80]  E. Smeraldi,et al.  Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine , 1998, Molecular Psychiatry.

[81]  B. Birmaher,et al.  Rapid response to psychosocial treatment for adolescent depression: a two-year follow-up. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[82]  G. Fava,et al.  Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. , 1998, The American journal of psychiatry.

[83]  G. Sethuraman,et al.  Parenteral clomipramine challenge in depressed adolescents: mood and neuroendocrine response , 1998, Biological Psychiatry.

[84]  B. Birmaher,et al.  Practice Parameters for the Assessment and Treatment of Children and Adolescents With Depressive Disorders , 1998 .

[85]  B. Birmaher,et al.  Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[86]  G. Fava,et al.  Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. , 1998, Archives of general psychiatry.

[87]  M. Carskadon,et al.  Sleep schedules and daytime functioning in adolescents. , 1998, Child development.

[88]  F. Sallee,et al.  Platelet serotonin transporter in depressed children and adolescents: 3H-paroxetine platelet binding before and after sertraline. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[89]  A. Rush,et al.  Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder , 1998, Biological Psychiatry.

[90]  A. Beck,et al.  Use of the Beck Depression Inventory-II with Adolescent Psychiatric Outpatients , 1998 .

[91]  R. Entsuah,et al.  A meta-analysis of the effects of venlafaxine on anxiety associated with depression. , 1998, Journal of clinical psychopharmacology.

[92]  G. Fava,et al.  Well-being therapy. A novel psychotherapeutic approach for residual symptoms of affective disorders , 1998, Psychological Medicine.

[93]  D J Kupfer,et al.  Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. , 1997, Archives of general psychiatry.

[94]  A. Rush,et al.  A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. , 1997, Archives of general psychiatry.

[95]  P. Bearman,et al.  Protecting adolescents from harm: Findings from the National Longitudinal Study on Adolescent Health. , 1997 .

[96]  S Iyengar,et al.  A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. , 1997, Archives of general psychiatry.

[97]  Martin H. Teicher,et al.  A controlled trial of light therapy for the treatment of pediatric seasonal affective disorder. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[98]  J. Rey,et al.  An epidemiological study of the use of ECT in adolescents. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[99]  A. Szegedi,et al.  Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out‐patients with inadequate treatment response , 1997, Acta psychiatrica Scandinavica.

[100]  M. Kovács,et al.  Psychiatric Disorders in Youths With IDDM: Rates and Risk Factors , 1997, Diabetes Care.

[101]  Barry R. Rittberg,et al.  The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. , 1996, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[102]  R. Harrington,et al.  Pilot study of continuation cognitive-behavioral therapy for major depression in adolescent psychiatric patients. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[103]  R. Harrington,et al.  Controlled trial of a brief cognitive-behavioural intervention in adolescent patients with depressive disorders. , 1996, Journal of child psychology and psychiatry, and allied disciplines.

[104]  J. Kelsey.  Dose-Response Relationship With Venlafaxine , 1996, Journal of clinical psychopharmacology.

[105]  R. Joffe,et al.  Response to an open trial of a second SSRI in major depression. , 1996, The Journal of clinical psychiatry.

[106]  Alain Martin,et al.  A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients , 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[107]  P. Szatmari,et al.  Predicting the one-year course of adolescent major depression. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[108]  M. Fava,et al.  Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. , 1995, The American journal of psychiatry.

[109]  P. Hazell,et al.  Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis , 1995, BMJ.

[110]  W. Hawkins,et al.  Targeted prevention of unipolar depressive disorder in an at-risk sample of high school adolescents: a randomized trial of a group cognitive intervention. , 1995, Journal of the American Academy of Child and Adolescent Psychiatry.

[111]  R. Harrington,et al.  Properties of the mood and feelings questionnaire in adolescent psychiatric outpatients: a research note. , 1995, Journal of child psychology and psychiatry, and allied disciplines.

[112]  M. Abou-Saleh,et al.  Placebo‐controlled trial of lithium augmentation of fluoxetine and lofepramine , 1995, British Journal of Psychiatry.

[113]  G. Clerc,et al.  A double‐blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia , 1994 .

[114]  J. Amsterdam,et al.  Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. , 1994, The American journal of psychiatry.

[115]  G. Fava,et al.  Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. , 1994, The American journal of psychiatry.

[116]  D. Guthrie,et al.  One-year outcomes of depressive disorders in child psychiatric in-patients: evaluation of the prognostic power of a brief measure of expressed emotion. , 1993, Journal of child psychology and psychiatry, and allied disciplines.

[117]  P. Lewinsohn,et al.  Cognitive-behavioral group treatment of adolescent depression: Prediction of outcome , 1992 .

[118]  J. Asarnow.  Suicidal Ideating and Attempts During Middle Childhood: Associations With Perceived Family Stress and Depression Among Child Psychiatric Inpatients , 1992 .

[119]  M. Thase,et al.  Tranylcypromine versus imipramine in anergic bipolar depression. , 1991, The American journal of psychiatry.

[120]  P. Lewinsohn,et al.  Cognitive-behavioral treatment for depressed adolescents* , 1990 .

[121]  A. Bifulco,et al.  Loss of parent in childhood and adult psychiatric disorder: A tentative overall model , 1990, Development and Psychopathology.

[122]  N. Ryan,et al.  MAOIs in adolescent major depression unresponsive to tricyclic antidepressants. , 1988, Journal of the American Academy of Child and Adolescent Psychiatry.

[123]  M. Strober,et al.  Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation. , 1982, Archives of general psychiatry.

[124]  J. McClellan,et al.  Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[125]  J. Weisz,et al.  Effects of psychotherapy for depression in children and adolescents: a meta-analysis. , 2006, Psychological bulletin.

[126]  A. Beautrais,et al.  Subthreshold depression in adolescence and mental health outcomes in adulthood. , 2005, Archives of general psychiatry.

[127]  M. Stein.  Sweating away the blues: can exercise treat depression? , 2005, American journal of preventive medicine.

[128]  Michel Hersen,et al.  Comprehensive handbook of psychological assessment , 2004 .

[129]  B. Birmaher,et al.  Lifetime history of sexual abuse, clinical presentation, and outcome in a clinical trial for adolescent depression. , 2004, The Journal of clinical psychiatry.

[130]  J. Stockman,et al.  Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. , 2004, JAMA.

[131]  S. Woods,et al.  Is there a SSRI dose response in treating major depression? The case for re‐analysis of current data and for enhancing future study design , 2003, Depression and anxiety.

[132]  Richard A. Brown,et al.  Psychiatric disorders, familial factors and cigarette smoking: I. Associations with smoking initiation. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[133]  M. Thase.  New approaches to managing difficult-to-treat depressions. , 2003, The Journal of clinical psychiatry.

[134]  R. Tweedie,et al.  Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. , 2003, Depression and anxiety.

[135]  G. Diamond,et al.  Attachment-based family therapy for depressed adolescents: a treatment development study. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[136]  M. Williams,et al.  Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder. , 2001, The American journal of psychiatry.

[137]  S Iyengar,et al.  Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. , 2000, Archives of general psychiatry.

[138]  L. Altshuler,et al.  Fluoxetine and sertraline dosages in major depression , 1999, Depression and anxiety.

[139]  E. Corruble,et al.  Existe-t-il une relation entre efficacité clinique et posologie d'antidépresseurs dans la dépression majeure ? , 1999 .

[140]  B. Capolaghi,et al.  [Fluoxetine: relations between plasma concentration and therapeutic effects in 32 patients with major depression and treated with 20 mg/day]. , 1998, L'Encephale.

[141]  T. Carmody,et al.  Fluoxetine in child and adolescent depression: Acute and maintenance treatment , 1998, Depression and anxiety.

[142]  J. McClellan,et al.  Summary of the practice parameters for the assessment and treatment of children and adolescents with posttraumatic stress disorder. American Academy of Child and Adolescent Psychiatry. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[143]  D. Fergusson,et al.  Factors protecting against the development of adjustment difficulties in young adults exposed to childhood sexual abuse. , 1997, Child abuse & neglect.

[144]  G. Diamond,et al.  Current status of family-based outcome and process research. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[145]  J. Fawcett,et al.  Response of anxiety and agitation symptoms during nefazodone treatment of major depression. , 1995, The Journal of clinical psychiatry.

[146]  M. Kovacs.  The Children's Depression, Inventory (CDI). , 1985, Psychopharmacology bulletin.

[147]  L. Freeman,et al.  Children's Depression Rating Scale - Revised (September 1984) , 1985 .